| Telomere maintenance as therapeutic target in embryonal tumours. | |
| | |
MedLine Citation:
|
PMID: 20017721 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Embryonal tumours most commonly occur in the first few years of life and account for approximately 30% of childhood malignancies. Knowledge of these tumours' genetics has already impacted on their clinical management and further knowledge of their cellular immortalization will hopefully result in novel therapies. The ends of human chromosomes are capped and protected by telomeres; cellular replication, however, causes their loss. A critical length of telomere repeats is required to ensure proper telomere function and avoid the activation of DNA damage pathways that result in senescence and cell death. To proliferate beyond the senescence checkpoint, cells must restore their telomere length. Hence stabilization of telomere is an important step in cell immortalization and carcinogenesis. Telomere maintenance is evident in virtually all types of malignant cells, including embryonal tumours, where either a telomerase-dependent or alternative lengthening of telomeres (ALT) mechanism is employed in order to ensure their limitless replicative potential. For this reason effective strategies targeting telomere maintenance in cancer cells require a combination of telomerase and ALT inhibitors. In this review, we are giving an overview about telomere maintenance in childhood tumours and discussing its potential as a new therapeutic target. |
| | |
Authors:
|
T Shalaby; E Hiyama; M A Grotzer |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't; Review |
Journal Detail:
|
Title: Anti-cancer agents in medicinal chemistry Volume: 10 ISSN: 1875-5992 ISO Abbreviation: Anticancer Agents Med Chem Publication Date: 2010 Mar |
Date Detail:
|
Created Date: 2010-04-22 Completed Date: 2010-07-09 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 101265649 Medline TA: Anticancer Agents Med Chem Country: Netherlands |
Other Details:
|
Languages: eng Pagination: 196-212 Citation Subset: IM |
Affiliation:
|
Neuro-Oncology Program, Department of Oncology, University Children's Hospital of Zurich, Switzerland. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Animals Antineoplastic Agents / therapeutic use* Child Embryo, Mammalian / enzymology G-Quadruplexes / drug effects Hepatoblastoma / genetics Humans Medulloblastoma / genetics Mice Neoplasms, Germ Cell and Embryonal / drug therapy*, physiopathology Neuroblastoma / genetics Rhabdomyosarcoma / genetics Sarcoma, Ewing's / genetics Telomerase / antagonists & inhibitors, genetics, physiology* Telomere / drug effects, metabolism* Wilms Tumor / genetics |
| Chemical | |
Reg. No./Substance:
|
0/Antineoplastic Agents; EC 2.7.7.49/TERT protein, human; EC 2.7.7.49/Telomerase; EC 2.7.7.49/Tert protein, mouse |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Phosphoinositide 3-kinase gamma (PI3Kgamma) inhibitors for the treatment of inflammation and autoimm...
Next Document: Cannabinoids, Opioids and MDMA: Neuropsychological Interactions Related to Addiction.